Interestingly, we found that expression of COX-2 was greatly decreased in the CIP–MSN-treated group at 7 and 14 dpi, with 0.4- and 0.3-fold changes, respectively, compared with CIP treatment alone. The gene discussed is PTGS2; the disease is hereditary sensory and autonomic neuropathy.